Opinion
Video
Recent Updates in Bispecifics and Their Use in Clinical Practice
Author(s):
Panelists discuss how recent clinical trials have demonstrated promising outcomes in late-line relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies targeting B-cell maturation antigen (BCMA) (teclistamab, talquetamab) and GPRC5D showing overall response rates of 60% to -70% even in heavily pretreated patients, while CAR-T cell therapies like ciltacabtagene autoleucel and idecabtagene vicleucel have produced deep responses with median progression-free survival extending beyond one year in some studies, and emerging combination approaches of these novel agents with traditional therapies are showing potential to overcome resistance mechanisms and improve durability of response.
Video content above is prompted by the following:
- Can you briefly summarize key findings from clinical trials recently presented that are relevant to late-line RRMM?
